Business Highlights

CSL delivers an exceptional performance for the 12 months ended 30 June 2017. Our strong year reflects the successful execution of our strategy.

growth

 

CSL’s reported net profit after tax was US$1,337 million for the year ended 30 June 2017. On a constant currency basis#, net profit after tax was US$1,427 million.

CSL’s total revenue reached US$6,923 million, up 15% on a constant currency basis.

CSL Behring’s strong performance resulted in product sales of US$5,811 million, up 12% on a constant currency basis.

Acquired a majority stake in Chinese plasma fractionator Ruide.

 

efficiency

 

Extended CSL Plasma’s world leading plasma collection network opening a total of 29 new plasma collection centres.

Capacity expansion projects to position CSL to meet future demand continue across Australia, Germany, Switzerland, the UK and the US.

Exemplary track record of consistent and reliable supply of medicines.

 

influenza

 

Seqirus is on track to profitability.

A broad product portfolio driving total revenue for the period of US$900 million, up 23% at constant currency#.

Launched three new influenza products in the United States (US):

  • FLUAD®;
  • FLUCELVAX QUADRIVALENT®;
  • AFLURIA QUADRIVALENT®.

Successful production of cell based candidate influenza vaccine at commercial scale at Holly Springs, US.

 

innovation

 

R&D investment this year reached US$645 million.

Achieved successes in all four R&D strategic areas with new registrations, positive results in some of the largest clinical trials ever conducted in rare diseases and an exciting new collaboration.

Achieved US Food and Drug Administration (FDA) approval, including marketing exclusivity for seven years, of HAEGARDA®, subcutaneous C1-Exterase Inhibitor (C1-INH) replacement therapy to prevent Hereditary Angioedema (HAE) attacks.

Initiation of human trials to investigate three new breakthrough medicines involving monoclonal antibodies.

 

people and culture

 

 

More than 19,000 employees in over 30 countries drive CSL’s performance.

Publication of CSL’s third edition Code of Responsible Business Practice, building on our culture of integrity and responsible business practice.

Measured one point above IBM’s global benchmark for employee engagement in our relaunched employee feedback survey.

 

 

# Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance. For further details refer to the Directors’ Report.